Compare LKFN & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | ENOV |
|---|---|---|
| Founded | 1872 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Fluid Controls |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2009 | 2008 |
| Metric | LKFN | ENOV |
|---|---|---|
| Price | $60.40 | $22.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $67.00 | $48.13 |
| AVG Volume (30 Days) | 132.2K | ★ 1.0M |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $15.08 | $9.18 |
| Revenue Next Year | $5.18 | $4.69 |
| P/E Ratio | $21.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.00 | $21.00 |
| 52 Week High | $69.38 | $43.76 |
| Indicator | LKFN | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 42.07 |
| Support Level | $59.67 | $21.59 |
| Resistance Level | $62.50 | $22.37 |
| Average True Range (ATR) | 1.82 | 1.01 |
| MACD | -0.22 | 0.17 |
| Stochastic Oscillator | 17.48 | 36.36 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.